Syneron Medical Ltd. Expands Management Team

YOKNEAM, ISRAEL--(Marketwire - May 05, 2010) - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today the appointment of industry veteran Tom Albright as President and General Manager of the Company’s Topical Aesthetics Division. Mr. Albright will be responsible for the global launch of Syneron’s elure™ (a novel dermal product line based on Syneron’s proprietary enzyme, Melanozyme™).

Mr. Albright joins Syneron with over 27 years of drug, device and aesthetic-related sales and marketing experience. He has held leadership positions at several innovative companies, where he established a successful track record developing new products and businesses in the expanding aesthetics marketplace. Among other positions, Mr. Albright spent nearly 8 years from 2000 to 2008 at Allergen where he led the BOTOX Cosmetic launch, was later VP of BOTOX Global Strategic Marketing and was the commercial lead for the development of Latisse, the first prescription product for eyelash growth.

Louis P. Scafuri, Chief Executive Officer commented, “We are pleased to welcome Tom to Syneron’s management team. His direct and relevant industry experience and strong business network will be a vital contribution as we expand the size, breadth and depth of our offering with the launch of the elure™ product line.

Mr. Scafuri continued, “Our newly created position of President and General Manager of Topical Aesthetics Division serves as another important step to position Syneron’s market leadership in the dynamic aesthetics industry. We continue to believe there is tremendous opportunity to drive growth and market share over the next several years.”

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

Additional information can be found at www.syneron.com.